How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

887 results for

Rivastigmine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase

Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03573050 Recruitment Status : Completed First Posted : June 29, 2018 Last Update Posted : August 21, 2018

2018 Clinical Trials

22. Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h) Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03659435 Recruitment Status : Recruiting

2018 Clinical Trials

23. Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily). Full Text available with Trip Pro

Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily). To compare the once-daily rivastigmine patch 9.5 mg/24 h (10 cm(2) ) versus twice-daily capsule (12 mg/day) in Chinese patients with probable Alzheimer's disease (AD) (mini-mental state examination [MMSE] scores of 10-20).The primary objective was to demonstrate the noninferiority of patch (...) , vomiting, and diarrhea occurred less frequently in the patch group (15.8% vs. 28.7%).Rivastigmine patch 9.5 mg/24 h is effective and well tolerated in Chinese patients with probable AD.© 2016 John Wiley & Sons Ltd.

2016 CNS neuroscience & therapeutics Controlled trial quality: predicted high

24. Cholinesterase inhibitors in Alzheimer's disease: supplementary commission rivastigmine patches and galantamine

Cholinesterase inhibitors in Alzheimer's disease: supplementary commission rivastigmine patches and galantamine Executive Summary 1 Translation of the executive summary of the final report “Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin” (Version 1.0; Status: 03.02.2012). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. IQWiG Reports - Commission No. A09-05 Cholinesterase inhibitors in Alzheimer’s disease: supplementary commission rivastigmine patches and galantamine 1 Executive summary of final report A09-05 Version 1.0 Cholinesterase inhibitors – rivastigmine patches/galantamine 03.02.2012 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Cholinesterase inhibitors in Alzheimer’s disease: supplementary

2012 Institute for Quality and Efficiency in Healthcare (IQWiG)

25. Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial. Full Text available with Trip Pro

Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial. Studies investigating the impact of white matter hyperintensities (WMHs) on the response of acetylcholinesterase inhibitors in patients with Alzheimer's disease (AD) have presented inconsistent results. We aimed to compare the effects of the rivastigmine (...) patch between patients with AD with minimal WMHs and those with moderate WMHs.Three hundred patients with mild to moderate AD were enrolled in this multicenter prospective open-label study and divided into two groups. Group 1 comprised patients with AD with minimal WMHs and group 2 comprised those with moderate WMHs. The patients were treated with a rivastigmine patch for 24 weeks. Efficacy measures were obtained at baseline and after 24 weeks. The primary endpoint was the change in the AD

2017 PLoS ONE

26. Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study. Full Text available with Trip Pro

Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study. To assess the efficacy and safety of transdermal rivastigmine for the treatment of HIV-associated cognitive impairment.We recruited HIV-infected patients with cognitive impairment on stable antiretroviral therapy in a randomized controlled pilot trial with a 48-week follow-up. An additional assessment was held at 12 weeks. Participants received transdermal rivastigmine (9.5 mg daily), lithium (400 mg (...) no significant differences between the arms (mean NPZ-7 change [SD]): rivastigmine, 0.35 (0.14); lithium, 0.25 (0.40); control, 0.20 (0.44) (p = 0.78). The rivastigmine group showed the highest positive trend (mean NPZ-7 [SD], baseline vs week 48): rivastigmine, -0.47 (0.22) vs -0.11 (0.29), p = 0.06; lithium, -0.50 (0.40) vs -0.26 (0.21), p = 0.22; control, -0.52 (0.34) vs -0.32 (0.52), p = 0.44. The cognitive domains with the highest positive trends were information processing speed at week 12

2017 PLoS ONE Controlled trial quality: uncertain

27. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer&#39

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer' Overview | Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance | NICE Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance [TA217] Published date: 23 March 2011 Last updated: 20 June 2018 Share Save Guidance on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (...) (Ebixa) for treating Alzheimer's disease in adults. This guidance has been partially updated by NICE’s guideline on (NG97) and replaces NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111). Guidance development process Is this guidance up to date? . We identified nothing new that affects recommendations 1.1, 1.2, 1.4, 1.5 and 1.6. Recommendation 1.3 was updated in June 2018 in NICE’s guideline on dementia (NG97

2011 National Institute for Health and Clinical Excellence - Technology Appraisals

28. [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine]

[Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine] Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine] Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin [Cholinesterase inhibitors in Alzheimer's disease - supplementary (...) commission: rivastigmine patches and galantamine] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin. [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine] Cologne: Institut fuer

2012 Health Technology Assessment (HTA) Database.

29. Donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease: a Bayesian network meta-analysis

Donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease: a Bayesian network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2018 PROSPERO

30. Rivastigmine

Rivastigmine Rivastigmine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Rivastigmine Rivastigmine Aka: Rivastigmine , Exelon II (...) . Indications III. Mechanism See -based noncompetitive Inhibits butyrylcholinesterase and acetylcholinesterase Increases transmission IV. Pharmacokinetics: Oral Route Peak: 1 hour Duration: 10 hours V. Drug Interactions No significant s VI. Efficacy Modestly improves scores on s Benefits decrease after 40 weeks of treatment VII. Adverse Effects See Specific adverse effects reported for Rivastigmine, not seen with other s VIII. Dosing Oral Route Initial: 1.5 mg orally twice daily with food for at least 2

2018 FP Notebook

31. [Rivastigmine and Parkinson's disease without dementia : Impact on gait stability and frequency of falling]. (Abstract)

[Rivastigmine and Parkinson's disease without dementia : Impact on gait stability and frequency of falling]. 27599816 2017 05 08 2018 11 13 1435-1269 49 7 2016 Oct Zeitschrift fur Gerontologie und Geriatrie Z Gerontol Geriatr [Rivastigmine and Parkinson's disease without dementia : Impact on gait stability and frequency of falling]. 662-663 Amadori Kerstin K Klinik für Altersmedizin, Klinikum Frankfurt Höchst, Gotenstr. 6-8, 65929, Frankfurt a. M., Deutschland. Kerstin.amadori (...) @klinikumfrankfurt.de. ger Clinical Trial, Phase II Journal Article Randomized Controlled Trial Rivastigmin und M. Parkinson ohne Demenz : Auswirkungen auf Gangstabilität und Sturzhäufigkeit. Germany Z Gerontol Geriatr 9506215 0948-6704 0 Cholinesterase Inhibitors PKI06M3IW0 Rivastigmine IM Accidental Falls prevention & control Aged Aged, 80 and over Cholinesterase Inhibitors administration & dosage Double-Blind Method Female Gait Disorders, Neurologic drug therapy etiology Humans Male Middle Aged Outcome

2017 Zeitschrift Fur Gerontologie Und Geriatrie Controlled trial quality: uncertain

32. Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits Full Text available with Trip Pro

Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits Rivastigmine has been shown to improve cognition in HIV+ patients with minor neurocognitive disorders; however, the mechanisms underlying such beneficial effect are currently unknown. To assess whether rivastigmine therapy is associated with decreased brain inflammation and damage, we performed T1/T2* relaxometry and magnetization transfer imaging in 17 aviremic HIV+ patients with minor neurocognitive disorders (...) enrolled on a crossed over randomized rivastigmine trial. Rivastigmine therapy was associated with changes in MRI metrics indicating a decrease in brain water content (i.e., edema reabsorption) and/or reduced demyelination/axonal damage. Furthermore, MRI changes correlated with cognitive improvement on rivastigmine therapy.

2017 Annals of clinical and translational neurology Controlled trial quality: uncertain

33. Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson's Dementia Complex: New Aspects for This Riddle Full Text available with Trip Pro

Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson's Dementia Complex: New Aspects for This Riddle Over 90% of PDD patients show at least one neuropsychiatric symptom (NPS); in the 60-70% two or more NPS are present. Their incidence is important in terms of prognosis and severity of pathology. However, among all NPS, apathy is often the most disturbing, associated with greater caregiver's burden. Similar to other NPS, apathy may be due to a dysfunction of the nigrostriatal pathway (...) , even though, not all the PD patients become apathetic, indicating that apathy should not entirely be considered a dopamine-dependent syndrome, and in fact it might also be related to acetylcholine defects. Apathy has been treated in many ways, without sure benefits; among these, Rivastigmine may present benefic properties. We present a series of 48 patients, suffering from PDD, treated with Rivastigmine, and followed-up for one year; they have been devotedly studied for apathy, even though all

2017 Parkinson's disease

34. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia Full Text available with Trip Pro

Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition with rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD). Unlike donepezil and galantamine that selectively inhibit acetylcholinesterase (AChE; EC 3.1.1.7), rivastigmine is a unique cholinesterase (...) inhibitor with both AChE and butyrylcholinesterase (BuChE; EC 3.1.1.8) inhibitory activity. Rivastigmine is also available as transdermal patch that has been approved by the US Food and Drug Administration for the treatment of mild, moderate, and severe AD as well as mild-to-moderate PDD. In this review, we explore the role of BuChE inhibition in addition to AChE inhibition with rivastigmine in the outcomes of cognition, global function, behavioral symptoms, and activities of daily living. Additionally

2017 Clinical interventions in aging

35. The First Use of Pralidoxime in a Child With Rivastigmine Poisoning. (Abstract)

The First Use of Pralidoxime in a Child With Rivastigmine Poisoning. The aim of this report is to describe the successful use of pralidoxime in a pediatric patient who accidentally ingested 12 mg of rivastigmine and presented to the emergency department with weakness, drowsiness, hyporeactivity to environmental stimuli, and full cholinergic syndrome.The patient presented to the emergency department 2 hours after a suspected ingestion of rivastigmine. He was sleepy but oriented and cooperative (...) , hypotonic, and hyporeflexic and has a Glasgow Coma Scale score of 13 (E3M6V4). Laboratory tests showed a low plasma cholinesterase levels of 2141 U/L (reference range, 5300-12 900 U/L), hyperglycemia (251 mg/dL), and leukocytosis with neutrophilia (21 900/mL, 75.2% neutrophils).Only 2 pediatric cases of rivastigmine poisoning have been reported in the literature, and there are no previous reports of using pralidoxime in the management of this poisoning. In the present case, intravenous pralidoxime (30

2017 Pediatric Emergency Care

36. Rivastigmine Actavis

Rivastigmine Actavis 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8545 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union 6 June 2011 EMA/454217/2011 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Rivastigmine Actavis International nonproprietary name: Rivastigmine Procedure No. EMEA/H/C/2036 Assessment Report as adopted by the CHMP with all information (...) an application for Marketing Authorisation to the European Medicines Agency (EMA) for Rivastigmine Actavis, through the centralised procedure falling within the scope of the Article 3 (3) – ‘Generic of a Centrally authorised product’ of Regulation (EC) No. 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 24/09/2009. The application concerns a generic medicinal product as defined in Article 10(2)(b) of Directive 2001/83/EC and refers to a reference product for which

2011 European Medicines Agency - EPARs

37. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models

Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 NHS Economic Evaluation Database.

38. Acquired Localized Hypertrichosis Induced by Rivastigmine Full Text available with Trip Pro

Acquired Localized Hypertrichosis Induced by Rivastigmine Hypertrichosis is the excessive hair growth in any area of the skin surface. Acquired localized hypertrichosis may be secondary to multiple causes and there is a secondary form due to several drugs, which is usually reversible with discontinuation of the causative agent. Rivastigmine is a reversible and competitive inhibitor of acetylcholinesterase and butyrylcholinesterase used for symptomatic treatment of Alzheimer dementia (...) and Parkinson's disease. It has an adequate safety profile and cutaneous side effects are unusual. Irritant contact dermatitis, allergic dermatitis, baboon syndrome, and cutaneous rash due to rivastigmine have been reported. We report on a Caucasian 80-year-old male with personal history of Alzheimer's disease. The patient started therapy with oral rivastigmine one month prior to clinical presentation of localized hypertrichosis on both forearms. Norgalanthamine has been shown to promote hair growth activity

2016 Case reports in dermatological medicine

39. Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer’s disease mouse model Full Text available with Trip Pro

Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer’s disease mouse model Recently, we showed that rivastigmine decreased amyloid-β (Aβ) brain load in aged rats by enhancing its clearance across the blood-brain barrier (BBB) via upregulation of P-glycoprotein (P-gp) and low-density lipoprotein receptor-related protein 1 (LRP1). Here, we extend our previous work to clarify P-gp role in mediating rivastigmine effect on Aβ brain (...) levels and neuroprotection in a mouse model of Alzheimer's disease (AD) that expresses different levels of P-gp. APPSWE mice were bred with mdr1a/b knockout mice to produce littermates that were divided into three groups; APP(+)/mdr1(+/+), APP(+)/mdr1(+/-) and APP(+)/mdr1(-/-). Animals received rivastigmine treatment (0.3mg/kg/day) or vehicle for 8weeks using Alzet osmotic mini-pumps. ELISA analysis of brain homogenates for Aβ showed rivastigmine treatment to significantly decrease Aβ brain load

2016 Biochimica et biophysica acta

40. Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats Full Text available with Trip Pro

Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats The treatment of depression in old age is complicated by frequent co-morbidity with cognitive impairment. Anti-dementia drugs have some efficacy to improve cognitive performance and there is an inconsistent literature regarding the effect of such drugs on depressive symptoms. Here, we have investigated whether anti-dementia drugs would have antidepressant-like and pro (...) -cognitive effects in a well-validated animal model of depression and cognitive impairment, chronic mild stress (CMS).Rats were subjected to CMS for a total of 8 weeks. After 2 weeks, subgroups of stressed and non-stressed animals were treated daily, for 5 weeks followed by 1 week of drug withdrawal, with vehicle, imipramine (10 mg/kg), rivastigmine (2 mg/kg), donepezil (0.3 mg/kg) or memantine (5 mg/kg). Sucrose intake was tested weekly, and animals were also tested in the elevated plus maze (at week 7

2016 Psychopharmacology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>